SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: margie who wrote (5563)10/21/1998 9:20:00 AM
From: margie  Read Replies (1) of 6136
 
BTW, last night, Bob Pisani on CNBC said that Agouron beat First Call estimates by .04 cents. He referred to Agouron as "one of those designer" companies, or maybe he said they make "designer" drugs.

and Briefing Com reported that:
<Agouron Pharmaceuticals (AGPH) 36 7/8 unch: company reports Q1 net of $0.21 a share, 4 cents above the First Call
mean estimate, vs yr-ago earnings of $0.11..

Elise Wang congratulated Agouron and also thanked them for meeting her numbers :-)

And I don't think I said you were short, Alexander. I just thought you were "looking for information in all the wrong places."

So much for Whisper numbers etc...

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News